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Available online 14 January 2016The KCL017 human embryonic stem cell linewas derived from an embryo donated for research that carried an au-
tosomal dominantmutation affecting splicing site of the VHL gene encoding von Hippel–Lindau tumor suppressor
E3 ubiquitin protein ligase (676 + 3 A N T). The ICM was isolated using laser microsurgery and plated on γ-
irradiated human foreskin ﬁbroblasts. Both the derivation and cell line propagation were performed in an animal
product-free environment. Pluripotent state and differentiation potential were conﬁrmed by in vitro assays.
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Differentiation potential into three germ layers was veriﬁed in vitro.
Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consentcy markers. Pluripotency is conﬁrmed by immunostaining (Oct
ne-phalloidin (red), are present in both feeders and hES cell col
of the couple undergoing PGD for the VHL syndrome.back to us and that might be months after the PIS and consent were
mailed to them. If in themeantime new versions of PIS/consent are im-
plemented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (PGD-V.6) were created on Aug. 10, 2007.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 — R.1 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Aug. 12, 2009. HFEA Code of Practice
that was in effect at the time of donor signature: Edition 7 — R.4. HFEA
Code of Practice Edition 7 – R.1was in effect until 09 Dec. 2007 and Edi-
tion 7 — R.4 was in effect: 02 Oct. 2008–30 Sep. 2009.Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically fromoutgrowth (Ilic et al., 2007; Ilic et al., 2010). hES colonies
were expanded and cryopreserved at the third passage.Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, and mycoplasma).4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
onies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
Table 1
Genotyping. Microsatellite markers speciﬁc for chromosomes 13, 18, 21, X and Y were
ampliﬁed. The allele sizes in bp for markers on chromosomes 13, 18, and 21 are listed in
the table.
Chr Marker Allele 1 Allele 2
13
D13S252 295 295
D13S305 450 454
D13S325 281 290
D13S628 450 457
D13S634 401 408
18
D18S386 363 378
D18S390 372 372
D18S391 214 218
D18S535 478 482
D18S819 412 416
D18S976 480 483
D18S978 211 220
21
D21S11 245 249
D21S1409 213 225
D21S1411 313 321
D21S1435 185 185
D21S1437 331 331
Fig. 3.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm
and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 100 μm.
270 H. Hewitson et al. / Stem Cell Research 16 (2016) 268–270Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012; Petrova et al.,
2014).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro as described (Ilic et al., 2012; Stephenson et al., 2012; Petrova
et al., 2014).
Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions.Ampliﬁcation of polymorphic microsatellite markers was carried out
as described (Ilic et al., 2012). Allele sizeswere recorded to give a unique
ﬁngerprint of each cell line.
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
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